LONG BEACH, Calif.--(BUSINESS WIRE)--Obagi Medical Products, Inc. (Nasdaq:OMPI), a leader in topical aesthetic and therapeutic skin health systems, today announced that it has filed a registration statement with the Securities and Exchange Commission (SEC) relating to a proposed secondary offering of up to 6,247,154 shares of its common stock. All of the shares of common stock to be registered are previously issued and currently outstanding shares that will, to the extent such shares are offered and sold, be offered and sold by existing stockholders of the Company. Obagi will not sell any shares in the offering and will not receive any of the proceeds from sales of the shares. The filing was made pursuant to the exercise of registration rights by a selling stockholder under the Investors’ Rights Agreement entered into in December 1997, as amended, between the Company and certain stockholders. Another stockholder is also entitled to participate in the offering pursuant to the Investors’ Rights Agreement and the shares held by that stockholder have also been included in the total shares registered in the registration statement. The registration of these shares does not necessarily mean that the selling stockholders will offer or sell all or any of the shares being registered.
